Skip to main content

Advertisement

SpringerLink
Log in

Ischemic index changes in diabetic retinopathy after intravitreal dexamethasone implant using ultra-widefield fluorescein angiography: a pilot study

  • Original Article
  • Published:
Acta Diabetologica Aims and scope Submit manuscript

Abstract

Aims

To investigate the effect of dexamethasone intravitreal implant on peripheral ischemia in patients affected by diabetic macular edema (DME).

Methods

Patients with treatment-naïve diabetic retinopathy (DR) undergoing intravitreal dexamethasone implant for DME between October 2015 and March 2017 were enrolled. Patients underwent a comprehensive ocular examination at baseline (<2 weeks before treatment) and 10 ± 2 weeks after dexamethasone implant including best-corrected visual acuity (BCVA), intraocular pressure, optical coherence tomography, ultra-widefield (UWF) retinography and UWF fluorescein angiography (UWFA).

Results

Nine eyes of seven consecutive patients (five males; mean age 66.4 ± 6.7 years) were enrolled. Mean duration of DR was 12.3 ± 8.4 years. Mean interval between UWFA acquisitions was 12.1 ± 2.1 weeks, and the mean interval between intravitreal injection and UWFA acquisition was 11.0 ± 1.6 weeks. Mean pre- and post-injection BCVA was 0.30 ± 0.20 and 0.21 ± 0.14 logMAR (p = 0.06), respectively. Mean pre- and post-injection central macular thickness was 449.8 ± 92.5 and 356.3 ± 52.4 μm (p = 0.03), respectively. Mean pre- and post-injection ischemic index was 24.0 ± 25.0 and 9.8 ± 12.1% (p = 0.0427), respectively.

Conclusions

Intravitreal dexamethasone implant reduces peripheral retina ischemia in patients with DR.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Wessel MM, Nair N, Aaker GD, Ehrlich JR, D’Amico DJ, Kiss S (2012) Peripheral retinal ischaemia, as evaluated by ultra-widefield fluorescein angiography, is associated with diabetic macular oedema. Br J Ophthalmol 96(5):694–698. doi:10.1136/bjophthalmol-2011-300774

    Article  PubMed  PubMed Central  Google Scholar 

  2. Witmer MT, Kiss S (2013) Wide-field imaging of the retina. Surv Ophthalmol 58(2):143–154. doi:10.1016/j.survophthal.2012.07.003

    Article  PubMed  Google Scholar 

  3. Diabetic retinopathy study (1981) Report number 6. Design, methods, and baseline results. Report number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. Invest Ophthalmol Vis Sci 21(2):1–226

    Google Scholar 

  4. Soliman AZ, Silva PS, Aiello LP, Sun JK (2012) Ultra-wide field retinal imaging in detection, classification, and management of diabetic retinopathy. Semin Ophthalmol 27(5–6):221–227. doi:10.3109/08820538.2012.708812

    Article  PubMed  Google Scholar 

  5. Nguyen QD, Brown DM, Marcus DM et al (2012) Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 119(4):789–801. doi:10.1016/j.ophtha.2011.12.039

    Article  PubMed  Google Scholar 

  6. Campochiaro PA, Wykoff CC, Shapiro H, Rubio RG, Ehrlich JS (2014) Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema. Ophthalmology 121(9):1783–1789. doi:10.1016/j.ophtha.2014.03.021

    Article  PubMed  Google Scholar 

  7. Bressler NM, Edwards AR, Beck RW et al (2009) Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Arch Ophthalmol 127(12):1566–1571. doi:10.1001/archophthalmol.2009.308

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Malcles A, Dot C, Voirin N et al (2016) Real-life study in diabetic macular edema treated with dexamethasone implant: the reldex study. Retina. doi:10.1097/IAE.0000000000001234

    Google Scholar 

  9. Haller JA, Bandello F, Belfort R Jr et al (2011) Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 118(12):2453–2460

    Article  PubMed  Google Scholar 

  10. Patel RD, Messner LV, Teitelbaum B, Michel KA, Hariprasad SM (2013) Characterization of ischemic index using ultra-widefield fluorescein angiography in patients with focal and diffuse recalcitrant diabetic macular edema. Am J Ophthalmol 155(6):1038–1044 e1032. doi:10.1016/j.ajo.2013.01.007

    Article  PubMed  Google Scholar 

  11. Tan CS, Sadda SR, Hariprasad SM (2014) Ultra-widefield retinal imaging in the management of diabetic eye diseases. Ophthalmic Surg Lasers Imaging Retina 45(5):363–366. doi:10.3928/23258160-20140909-07

    Article  PubMed  Google Scholar 

  12. Wessel MM, Aaker GD, Parlitsis G, Cho M, D’Amico DJ, Kiss S (2012) Ultra-wide-field angiography improves the detection and classification of diabetic retinopathy. Retina 32(4):785–791. doi:10.1097/IAE.0b013e3182278b64

    Article  PubMed  Google Scholar 

  13. Wilkinson CP, Ferris FL 3rd, Klein RE et al (2003) Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 110(9):1677–1682. doi:10.1016/S0161-6420(03)00475-5

    Article  CAS  PubMed  Google Scholar 

  14. Sim DA, Keane PA, Rajendram R et al (2014) Patterns of peripheral retinal and central macula ischemia in diabetic retinopathy as evaluated by ultra-widefield fluorescein angiography. Am J Ophthalmol 158(1):144–153 e141. doi:10.1016/j.ajo.2014.03.009

    Article  PubMed  Google Scholar 

  15. Edelman JL, Lutz D, Castro MR (2005) Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp Eye Res 80(2):249–258. doi:10.1016/j.exer.2004.09.013

    Article  CAS  PubMed  Google Scholar 

  16. Tamura H, Miyamoto K, Kiryu J et al (2005) Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci 46(4):1440–1444. doi:10.1167/iovs.04-0905

    Article  PubMed  Google Scholar 

  17. Dugel PU, Bandello F, Loewenstein A (2015) Dexamethasone intravitreal implant in the treatment of diabetic macular edema. Clin Ophthalmol 9:1321–1335. doi:10.2147/OPTH.S79948

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Via Olgettina 60, Milan, 20132, Italy

    Lea Querques, Riccardo Sacconi, Alessandro Rabiolo, Francesco Bandello & Giuseppe Querques

  2. G. B. Bietti Foundation-IRCCS, Rome, Italy

    Lea Querques & Mariacristina Parravano

  3. Eye Clinic, Department of Neurological and Movement Sciences, University of Verona, Verona, Italy

    Riccardo Sacconi

Authors
  1. Lea Querques
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mariacristina Parravano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Riccardo Sacconi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alessandro Rabiolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Francesco Bandello
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Giuseppe Querques
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuseppe Querques.

Ethics declarations

Conflict of interest

Lea Querques, Alessandro Rabiolo, Maria Cristina Parravano, Riccardo Sacconi declare that they have no conflict of interest. Francesco Bandello consultant for: Alcon (Fort Worth, Texas, USA), Alimera Sciences (Alpharetta, Georgia, USA), Allergan Inc (Irvine, California, USA), Farmila-Thea (Clermont-Ferrand, France), Bayer Shering-Pharma (Berlin, Germany), Bausch And Lomb (Rochester, New York, USA), Genentech (San Francisco, California, USA), Hoffmann-La-Roche (Basel, Switzerland), NovagaliPharma (Évry, France), Novartis (Basel, Switzerland), Sanofi-Aventis (Paris, France), Thrombogenics (Heverlee, Belgium), Zeiss (Dublin, USA). Giuseppe Querques consultant for: Alimera Sciences (Alpharetta, Georgia, USA), Allergan Inc (Irvine, California, USA), Heidelberg (Germany), Novartis (Basel, Switzerland), Bayer Shering-Pharma (Berlin, Germany), Zeiss (Dublin, USA).

Ethical standard

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Human and animal rights

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Declaration of Helsinki 1975, as revised in 2008.

Informed consent

Informed consent was obtained from all patients for being included in the study.

Additional information

Managed by Antonio Secchi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Querques, L., Parravano, M., Sacconi, R. et al. Ischemic index changes in diabetic retinopathy after intravitreal dexamethasone implant using ultra-widefield fluorescein angiography: a pilot study. Acta Diabetol 54, 769–773 (2017). https://doi.org/10.1007/s00592-017-1010-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00592-017-1010-1

Keywords

Search

Navigation